Hyderabad-based manufacturer of generic pharmaceuticals and active pharmaceutical ingredients (APIs) Aurobindo Pharma has received a tentative approval from the US Food and Drug Administration (USFDA) to manufacture and market Losartan Potassium tablets in 25mg, 50mg and 100mg strengths. This is Aurobindo’s 75th abbreviated new drug application (ANDA) approval from the US FDA.
Losartan Potassium tablets are the generic equivalent of US-based Merck Research Laboratories’ Cozaar tablets and falls in the antihypertensive segment. The brand sales of Losartan range of products was $1,235 million for the year ended December 2007 according to Merck's financial disclosures, Aurobindo stated in a press release on Thursday.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app